Education
About Us
Working with TipRanks
Follow Us
Sab Biotherapeutics, Inc. (SABS)
:SABS
SABS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.11 - $5.01
Previous CloseN/A
Volume58.44K
Average Volume (3M)50.90K
Market Cap
$11.43M
Enterprise Value$19.12M
Total Cash (Recent Filing)$858.05K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.09
Next Earnings
May 08, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding9,288,868
10 Day Avg. Volume21,586
30 Day Avg. Volume50,899
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)10.51
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.70
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$11.00Price Target Upside794.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical PerformancePositive Phase 1 results for SAB-142 in healthy volunteers were announced, demonstrating a clinically validated multi-target mechanism of action with sustained immunomodulation and no sustained lymphodepletion.
Market OpportunityThe company's plans to potentially pursue other indications for SAB-142 in different stages of type 1 diabetes suggest a broader market opportunity.
Regulatory ProgressThe company announced that it received FDA clearance of the IND application for SAB-142, allowing T1D patients to enroll in the ongoing trial.
Bears Say
Regulatory And Clinical RisksRisks identified include commercial, regulatory, clinical, manufacturing, financial, liability, and intellectual property concerns.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SABS FAQ
What was Sab Biotherapeutics, Inc.’s price range in the past 12 months?
Sab Biotherapeutics, Inc. lowest stock price was $1.11 and its highest was $5.01 in the past 12 months.
What is Sab Biotherapeutics, Inc.’s market cap?
Sab Biotherapeutics, Inc.’s market cap is $11.43M.
When is Sab Biotherapeutics, Inc.’s upcoming earnings report date?
Sab Biotherapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Sab Biotherapeutics, Inc.’s earnings last quarter?
Sab Biotherapeutics, Inc. released its earnings results on Mar 31, 2025. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.005 by -$0.225.
Is Sab Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Sab Biotherapeutics, Inc.’s price is currently Undervalued.
Does Sab Biotherapeutics, Inc. pay dividends?
Sab Biotherapeutics, Inc. does not currently pay dividends.
What is Sab Biotherapeutics, Inc.’s EPS estimate?
Sab Biotherapeutics, Inc.’s EPS estimate is -1.01.
How many shares outstanding does Sab Biotherapeutics, Inc. have?
Sab Biotherapeutics, Inc. has 9,288,868 shares outstanding.
What happened to Sab Biotherapeutics, Inc.’s price movement after its last earnings report?
Sab Biotherapeutics, Inc. reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.005. Following the earnings report the stock price went down -8.108%.
Which hedge fund is a major shareholder of Sab Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in SABS
---
SAB Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (794.31% Upside)
$11.00 (794.31% Upside)
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.22%
12-Months-Change
Fundamentals
Return on Equity
-81.92%
Trailing 12-Months
Asset Growth
-45.12%
Trailing 12-Months
Company Description
Sab Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
---
SABS Stock 12 Month Forecast
Average Price Target
$11.00
▲(794.31% Upside)
Technical Analysis
Fate Therapeutics
―
Replimune Group
―
Allogene Therapeutics
―
Adaptive Biotechnologies
―
Immatics
―
Best Analysts Covering SABS
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-54.97%
reiterated a buy rating 3 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -54.97% per trade.
---